Paradox CA 15–3 increase in metastatic breast cancer patients treated with everolimus: a change of paradigm in a case series

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2

(2016) Gabriel N. Hortobagyi et al.   JOURNAL OF CLINICAL ONCOLOGY

PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer

(2015) Salvatore L. Burgio et al.   Clinical Genitourinary Cancer

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

(2015) Catherine Van Poznak et al.   JOURNAL OF CLINICAL ONCOLOGY

Caution for interstitial lung disease as a cause of CA 15-3 rise in advanced breast cancer patients treated with everolimus

(2014) Annelieke E.C.A.B. Willemsen et al.   INTERNATIONAL JOURNAL OF CANCER

Transient therapy-related surge in serum tumor biomarkers: Characterizing behavior and postulating its biologic role

(2012) Suneel D. Mundle et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers

(2012) Michael J. Duffy   MEDICAL PRINCIPLES AND PRACTICE

Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein

(2012) C Jin et al.   ONCOGENE

Dependence on the MUC1-C Oncoprotein in Non-Small Cell Lung Cancer Cells

(2011) D. Raina et al.   MOLECULAR CANCER THERAPEUTICS

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC)

(2011) Dorit Di Gioia et al.   TUMOR BIOLOGY

Clinical significance of a serum CA 15-3 surge and the usefulness of CA 15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer

(2010) Shih-Chung Wu et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting the human MUC1 oncoprotein: A tale of two proteins

(2010) Donald W. Kufe   CANCER BIOLOGY & THERAPY

Functional targeting of the MUC1 oncogene in human cancers

(2010) Donald W. Kufe   CANCER BIOLOGY & THERAPY

CA 15-3: Uses and limitation as a biomarker for breast cancer

(2010) Michael J. Duffy et al.   CLINICA CHIMICA ACTA

mTOR and cancer: many loops in one pathway

(2009) Alejo Efeyan et al.   CURRENT OPINION IN CELL BIOLOGY

MUC1 Oncoprotein Blocks Death Receptor-Mediated Apoptosis by Inhibiting Recruitment of Caspase-8

(2008) N. Agata et al.   CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer

(2008) Kan Yonemori et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Structure and Function of the Cell Surface (Tethered) Mucins

(2007) Christine L. Hattrup et al.   Annual Review of Physiology